FDA Approves First Immunotherapy for Initial Treatment of Gastric Cancer

The PD-1 checkpoint inhibitor Opdivo (nivolumab) has been approved by the FDA as an initial treatment for advanced gastric cancer, adding to its approvals as a treatment for melanoma and a number of other cancers.